Abstract Details

Title Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-based Study (2010-2015)

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 176

Objective To examine incidence and survival of Parkinson’s Disease (PD) and other parkinsonisms occurring before 50 or 55 years of age.

Background No previous studies have reported incidence of early-onset PD (EOPD) in a population-based cohort of parkinsonism.

Design/Methods We used a newly identified incident cohort of parkinsonism (<50 and <55 years) defined by the expanded Rochester Epidemiology Project (eREP) medical records-linkage system between 2010-15 in seven counties in Minnesota. A movement disorder specialist reviewed all charts to confirm the diagnoses.

Results We identified 27 patients with a diagnosis of incident parkinsonism in 2010-15 prior to 50 years of age: 11 (41%) early-onset PD (EOPD), 13 (48%) drug-induced parkinsonism (DIP), and 3 (11%) other parkinsonism. When expanding to include those with a diagnosis before 55 years of age, we found 69 incident cases of parkinsonism: 28 (41%) of both EOPD and DIP, and 13 (19%) of other parkinsonism. Incidence of parkinsonism (<50) was 1.98/100,000 person-years, in EOPD (<50) it was 0.81/100,000; whereas in parkinsonism (<55) it was 5.05/100,000, and in EOPD (<55) was 2.05/100,000.
Levodopa-induced dyskinesia (LID) was reported in 45% of both EOPD (<50) and (<55) and occurred after a median of 6.17 and 5.18 years after EOPD diagnosis, respectively. Onset of cardinal motor symptoms was proximate to EOPD diagnosis, with the exception of impaired postural reflexes, which followed EOPD (<50) by 4.33 years, and EOPD (<55) by 1.32 years.
In parkinsonism (<55), 9 (13%) were deceased at data collection day; all of them were men (1 only EOPD). Men had greater risk of mortality compared to women (p= 0.049).

Conclusions Incidence of both parkinsonism and EOPD was higher in men than women, regardless of the cut-off age chosen. LID was reported 5-6 years after EOPD diagnosis in about 45% of the EOPD. Men had a higher mortality compared to women, in parkinsonism (<55).

Authors/Disclosures
Emanuele Camerucci, MD (Kansas University Medical Center) PRESENTER	Dr. Camerucci has nothing to disclose.
Cole D. Stang	Mr. Stang has nothing to disclose.
Pierpaolo Turcano, MD (Rush University Medical Center)	Dr. Turcano has nothing to disclose.
Aidan Mullan (Mayo Clinic)	Aidan Mullan has nothing to disclose.
	No disclosure on file
Owen A. Ross, PhD (Mayo Clinic Jacksonville)	Dr. Ross has nothing to disclose.
James H. Bower, MD, MSc, F�鶹��ýӳ�� (Mayo Clinic)	The institution of Dr. Bower has received research support from Abbvie.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine)	Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Rodolfo Savica, MD, PhD, F�鶹��ýӳ�� (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.

�鶹��ýӳ��

�鶹��ýӳ��